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Most bone tissue–engineering research uses porous three-dimensional (3D) scaffolds for cell seeding. In this
work, scaffold-less 3D bone-like tissues were engineered from rat bone marrow stromal cells (BMSCs) and their
autogenous extracellular matrix (ECM). The BMSCs were cultured on a 2D substrate in medium that induced
osteogenic differentiation. After reaching confluence and producing a sufficient amount of their own ECM, the
cells contracted their tissue monolayer around two constraint points, forming scaffold-less cylindrical engineered
bone-like constructs (EBCs). The EBCs exhibited alizarin red staining for mineralization and alkaline phos-
phatase activity and contained type I collagen. The EBCs developed a periosteum characterized by fibroblasts
and unmineralized collagen on the periphery of the construct. Tensile tests revealed that the EBCs in culture had
a tangent modulus of 7.5 0.5 MPa at 7 days post-3D construct formation and 29 9 MPa at 6 weeks after
construct formation. Implantation of the EBCs into rats 7 days after construct formation resulted in further bone
development and vascularization. Tissue explants collected at 4 weeks contained all three cell types found in
native bone: osteoblasts, osteocytes, and osteoclasts. The resulting engineered tissues are the first 3D bone tissues
developed without the use of exogenous scaffolding.
Introduction
Approximately one million surgeries are performedeach year in the United States that require bone grafts to
replace tissue damaged by disease or extensive trauma.1
Several limitations are associated with grafting, such as graft
availability, donor site morbidity, and immune rejection.
Because of these complications, strategies are being devel-
oped to engineer bone tissue in vitro for bone replacement.
Current approaches to engineer bone involve the design of
a three-dimensional (3D) scaffold that promotes the differ-
entiation and proliferation of osteogenic cells and the depo-
sition and mineralization of an osteogenic extracellular
matrix (ECM). The scaffold design rubrics also include the
ability to withstand physiological loads in vivo and even-
tual incorporation into the native tissue or degradation
during the course of tissue development.2 Polymers such as
poly(lactic-co-glycolic acid), poly(propylene fumarates), and
poly(caprolactones) provide a matrix that promotes cell ad-
hesion and migration, allow for the deposition and miner-
alization of osteogenic ECM in vitro, and have predictable
degradation rates but lack the mechanical properties needed
to withstand the loads placed on natural bone in vivo.3–5
Hydroxyapatite and b-tricalcium phosphates are ceramics
used for bone scaffolding that also promote cell adhesion
and proliferation and when implanted have shown positive
results with regard to bone regeneration in vivo. However,
the brittle nature of ceramics inhibits their use in healing
large defects.2,6 Polymer–ceramic composite scaffolds such as
calcium phosphate salts embedded in poly(caprolactones)
have been designed to mitigate the problems with using each
material alone, but a significant percentage of cells fails to
attach to the composite scaffold because of limited surface-
to-volume ratio.7,8 Single-layer cell sheets grown from bone
marrow stromal cells (BMSCs) and wrapped around com-
posite scaffolds have recently been shown to form constructs
that resemble bone in vitro and in vivo.8 However, this
method still involves the use of an exogenous scaffolding
that must incorporate into native tissue.
BMSCs are multipotent cells that can differentiate in vitro
in response to chemical signals and generate and mineralize
their own autogenous ECM. BMSCs can be easily isolated
from autologous sources and therefore serve as an attractive
candidate for tissue engineering.9–12 Because a specific bone
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marker does not exist, an engineered tissue is characterized
as being bone according to a number of criteria. The presence
of alkaline phosphatase (ALP), an enzyme that cleaves phos-
phate ions from organic molecules, is a precursor to miner-
alization of bone and thus an early sign of bone formation.13
Bone is composed predominantly of type I collagen miner-
alized with hydroxyapatite crystals and contains osteocalcin,
so the presence of these molecules further substantiates dif-
ferentiation of BMSCs toward bone. The absence of type II
collagen, the predominant protein of cartilage, is often used
to exclude differentiation to cartilage. The structural prop-
erties of bone, including cells with an osteogenic morphology
and nucleation and growth of mineralized structures
through matrix vesicles or intrafibrillar mineralization, can
be monitored using light and electron microscopy.14 The
periosteum of bone is fibrous tissue found on the bone sur-
face that contains fibroblasts, osteoprogenitor cells, and un-
mineralized type I collagen. Osteoprogenitor cells differentiate
into osteoblasts during bone growth and remodeling.15 The
periosteum can be identified through microscopy because of
the elongated shape of fibroblasts and osteoprogenitor cells,
versus the round presentation of osteoblasts. The presence of
rows of osteoblasts between the fibrous periosteum and the
mineralized bone core is an indication of a functioning
periosteum because the osteoprogenitor cells are actively
differentiating to osteoblasts.
In this study, we developed a method to engineer 3D bone-
like tissue structures solely from BMSCs and their autogenous
ECM using an approach similar to one we previously devel-
oped for tissue engineering of soft tissues and their inter-
faces.16-18 Our method bypasses the many design challenges
and limitations associated with the engineering of composite
bone constructs with exogenous scaffolding. The successful
fabrication of engineered bone-like structures was confirmed
using histological and immunoflourescent markers for ALP
activity, type I collagen, osteocalcin, and absence of type II
collagen. The engineered tissues were further analyzed
structurally using transmission electron microscopy (TEM)
and functionally with tensile tests. Our autogenous matrix
engineered bone-like constructs were ectopically implanted
in vivo to investigate the effects of an in vivo environment on
the growth and development of the engineered tissue.
Methods
BMSC isolation and expansion
All animal care and animal surgeries were in accordance
with The Guide for Care and Use of Laboratory Animals
(Public Health Service, 1996, National Institutes of Health
Publication No. 85-23); the University of Michigan’s Com-
mittee for the Use and Care of Animals approved by the ex-
perimental protocol. Under aseptic conditions, bone marrow
was collected from the femur and tibia of female Fisher 344
rats. Briefly, the soft tissues of the leg were removed from the
femur and tibia, both ends of the bones were detached, and
the marrow flushed out using a syringe with a 25-gage needle
filled with Dulbecco’s modified Eagle medium (DMEM; Gibco,
Rockville, MD). The marrow was vortexed and then centri-
fuged at 480 g for 5 min using a ThermaForma General Pur-
pose Centrifuge (Waltham, MA). The pellet was resuspended
in 10 mL of growth medium (M1) consisting of DMEM with 20
volume % fetal bovine serum (Gibco), 6 ng=mL basic fibroblast
growth factor (bFGF; Peprotech, Rocky Hill, NJ ), 108 M
dexamethasone (dex; Sigma-Aldrich, St. Louis, MO ), and 1%
antibiotic-antimycotic (Gibco), and plated into 100-mm-di-
ameter tissue culture dishes. The dishes were kept in an in-
cubator at 378C, 95% humidity, and 5% carbon dioxide. After
48 h, the non-adherent cells were removed by replacing the
M1. The adherent BMSCs were cultured to 80% confluence, at
which time cells were enzymatically removed from the plate
using a 0.25% trypsin-ethylenediaminetetraacetic acid solu-
tion (Gibco) and passaged. Cells were plated onto construct
dishes during the third to fifth passages.
Construct dish preparation
Tissue culture plastic dishes, 35 mm in diameter (BD Bios-
ciences, San Jose, CA), were filled with 1.5 mL SYLGARD
(type 184 silicone elastomer; Dow Chemical, Midland, MI).
The polymer was allowed to cure for 3 weeks before use. The
SYLGARD was coated with 3 mg=cm2 natural mouse laminin
(Invitrogen, Carlsbad, CA) by filling dishes with 3 mL of a
9.6 mg=mL laminin solution in Dulbecco’s phosphate buff-
ered saline (DPBS; Gibco). The laminin solution was evapo-
rated overnight in a biosafety cabinet. Dishes were rinsed
once with DPBS and then filled with 1 mL of DMEM con-
taining 20% fetal bovine serum and 1% antibiotic-antimycotic.
The dishes were then sterilized via exposure to ultraviolet
radiation (wavelength, 253.7 nm; bulb G30T8) in a biological
safety cabinet for 60 min, then kept in an incubator for 5 to 8
days. After the incubation, the medium was aspirated from
the dish, and BMSCs were seeded onto each dish in 2 mL of
M1 supplemented with 0.13 mg=mL of L-ascorbic acid-2-
phosphate (asc-2-phos; Sigma-Aldrich) and 0.05 mg=mL of L-
proline (Sigma-Aldrich). There were 30 dishes in total, with an
initial cell density of 200,000 BMSCs=dish. The cells were fed
M1 supplemented with asc-2-phos and proline every 2 days
until confluence was reached. Once the cells reached conflu-
ence, two minutien pins, 0.2 mm in diameter and 1 cm long
(Fine Science Tools, San Francisco, CA), were pinned onto the
cell monolayer 1.5 cm apart. At confluence, the M1 was
switched to a second medium (M2), consisting of DMEM with
7% horse serum (Gibco), 0.13 mg=mL of asc-2-phos,
0.05 mg=mL of L-proline, and 2 ng=mL of transforming
growth factor beta (TGF-b; Peprotech). Ten of the 30 plates
also contained 6 ng=mL of bFGF and 108 M dex and received
the TGF-b at confluence (Bone Group 1), another 10 plates
were also supplied the bFGF, dex, and TGF-b, but the TGF-b
was administered 5 days after confluence (Bone Group 2). The
remaining 10 plates received TGF-b at confluence but did not
receive bFGF or dex (Bone Group 3). Table 1 lists the medium
formulations used in this study. There were no differences in
the ability of the cells in each population to form bone-like
constructs, and the resulting constructs had similar histolog-
ical structure and mechanical properties;19 therefore, results
were combined from the three sets. Seven days after construct
formation, the diameter of the samples was measured using
a reticule in the eyepiece of a Nikon SMZ1500 dissection
microscope (Melville, NY).
Histochemical and immunofluorescence staining
Seven days after 3D construct formation, the engineered
bone-like constructs (EBCs) were mounted on a holder us-
ing tissue freezing medium (Triangle Biomedical Sciences,
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Durham, NC) and immersed in 808C isopentane. The fro-
zen samples were sliced longitudinally to a thickness of 9mm
to 12 mm using a Microm HM 500 cryostat system (Heidel-
berg, Germany). The slides were then used for histological
staining for light microscopy or immunofluorescent staining.
For histochemical staining, tissue sections were fixed with
methanol and stained for calcification with Alizarin Red or
hematoxylin and eosin to observe tissue structure. The re-
maining sections were fixed in acetone and stained for ALP
activity.
Immunofluorescent staining was performed to detect the
presence of collagen I, collagen II, and osteocalcin. Frozen
sections were fixed with methanol for 5 min and rinsed three
times with DPBS. Sections were then blocked for 30 min with
Ham’s F-12 containing 5% donkey serum ( Jackson Immuno-
Research Labs, Inc, West Grove, PA) at 378C. Sections were
then incubated for 2 h with the primary antibodies in Ham’s
F-12 containing 1% donkey serum. The concentrations of each
of the antibodies were as follows: 5mg=mL of rabbit anti-rat
collagen I (Abcam Inc., Cambridge, MA), 5 mg=mL of mouse
anti-rat collagen II (Calbiochem, Darmstadt, Germany), and
10 mg=mL of mouse anti-rat osteocalcin (Abcam). Samples
were then rinsed three times with Ham’s F-12 and blocked
again in Ham’s F-12 containing 5% donkey serum at 378C for
10 min. The secondary antibodies (5 mg=mL) were then ap-
plied to the sections for 1 h as follows: Alexa Fluor 488 donkey
anti-rabbit immunoglobulin (Ig)G (Molecular Probes, Eugene,
OR) for collagen I, Alexa Fluor 555 donkey anti-mouse IgG
(Molecular Probes) for collagen II, and Alexa Fluor 488 donkey
anti-mouse IgG (Molecular Probes) for osteocalcin. Positive
and negative control stainings were performed using wheat
germ agglutinin lectin and primary antibody omission, re-
spectively (not shown). Nuclei were stained with Prolong
Gold antifade reagent with 4’,6-diamidino-2-phenylindole
(DAPI; Invitrogen). A Nikon Eclipse TS100 microscope
equipped with an X-Cite 120 Fluorescence Illumination Sys-
tem was used to image the histochemically and immuno-
fluorescently marked sections. Images were captured using a
Diagnostic Instruments Spot Insight Color camera (Sterling
Heights, MI).
Transmission electron microscopy
Samples were fixed for TEM in 2.5% glutaraldehyde (Elec-
tron Microscopy Sciences, Hatfield, PA) in 0.1 M of Sorensen’s
buffer, pH 7.4, for 24 h at 48C. Constructs were then thor-
oughly rinsed with Sorenson’s buffer and post-fixed with 1%
osmium tetroxide in Sorensen’s buffer for 2 h. Samples were
then rinsed with double distilled water and stained with 8%
uranyl acetate in double distilled water for 1 h. Constructs
were dehydrated in a graded series of ethanol, treated with
propylene oxide, and embedded in Epon 812. Longitudinal
ultra-thin sections, 70 nm thick, were prepared and stained
with uranyl acetate and lead citrate. The sections were exam-
ined using a Philips CM100 electron microscope (Bothell, WA)
at 60 kV. Images were digitally recorded using a Hamamatsu
ORCA-HR digital camera system (Hamamatsu City, Japan)
operated using AMT software (Advanced Microscopy Tech-
niques Corp., Danvers, MA).
Mechanical properties
Tensile tests were performed on EBCs engineered in vitro 7
days (n¼ 4) or 6 weeks (n¼ 3) after 3D construct formation.
Tests were performed using a custom tabletop tensiometer
designed in our laboratory, attached to a Nikon SMZ1500
dissection microscope. The sample was immersed in a bath
of DPBS, and the ends were grasped using clamps. The di-
mensions of the sample were measured before each test for
cross-sectional area calculation using a reticule in the eye-
piece of the microscope. Beads 25mm in diameter (Interac-
tive Medical Technologies, Irvine, CA) were brushed on the
surface of the sample as position markers for digital image
correlation analysis of tensile strain. Samples were stretched
at a strain rate of 0.01=s. Force was measured using a custom
force transducer and monitored using LABVIEW software
(National Instruments, Austin, TX); the resolution of the
force transducer used for testing the EBCs was 1 mN. Images
of the sample were captured using a Basler camera (Exton,
PA) attached to the Nikon dissection microscope at a fre-
quency of 2.5=s during the test to follow the location of the
digital image correlation markers. The bead position from
each image was recorded using LABVIEW software (Mel-
ville, NY) with a resolution of 5 mm, and length between
beads was calculated by subtracting the position of one bead




Table 1. The Time at Which Each Medium Formulation Was Initially Administered and the Media Formulations























Bone 3 DMEM, 7% HS, asc-2-phos, proline, TGF-b
All bone marrow stromal cells (BMSCs) received the same medium (M1) immediately after isolation. EBC construct dishes received
different medium (M2) after BMSCs reached confluence. EBCs from the three groups yielded the same histological and mechanical
properties; therefore results were combined.19
DMEM, Dulbecco’s modified Eagle medium; FBS, fetal bovine serum; dex, dexamethasone; HS, horse serum; asc-2-phos, L-ascorbic acid-
2-phosphate; bFGF, basic fibroblast growth factor; TGF-b, transforming growth factor beta.
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Where s is nominal stress, F is force, and A0 is the initial
cross-sectional area of the sample. Nominal strain was cal-
culated using the following equation:
e¼ l lo
lo
Where e is the nominal strain, l is the current length between
beads, and lo is the original length. Moduli were obtained by
calculating the slope of the tangent of stress versus strain
plots at the maximum strain before failure.
Implantation
Seven days after 3D construct formation, EBCs were
placed into a piece of sterile TYGON silicone tubing (United
States Plastics Corp., Lima, OH) that had an inner diameter
of 1.6 mm, an outer diameter of 3.2 mm, and a length of
1.5 cm. Fisher 344 rats were anesthetized using 0.001 mL of
Nembutal sodium solution (pentobarbital sodium injection;
Ovation Pharmaceutical Inc., Deerfield, IL) per gram of the
animal’s weight. The silicone tubes containing the constructs
were then implanted between the biceps femoris and the
quadriceps of the left leg of the host animals. The silicone
tubing was used to identify the engineered tissue during
explantation.
Four weeks after implantation, constructs were removed
from the animal. The diameter of the explants was mea-
sured using electronic calipers. The samples were then frozen
and mounted in tissue freezing medium and stored at 808C
or fixed in 2.5% glutaraldehyde and mounted in paraffin for
histological studies.
X-ray diffraction
Wide-angle X-ray scattering diffraction was performed on
EBC (n¼ 2) samples 6 weeks in culture post-3D construct
formation. The bone constructs were removed from their
medium and allowed to dry. The engineered tissues were
placed on a single-crystal silicon substrate and examined
using a Bruker (D8 Discover) diffractometer (Madison, WI)
using Cu Ka radiation and a source voltage of 40 kV. The
samples were investigated over a 2y range of 238 to 558 with
20 counts recorded per degree. Scattering resulting from the
substrate was subtracted, and resulting peaks were identified
using the hydroxyapatite Powder Diffraction File from the
Joint Committee on Powder Diffraction Standards (Swarth-
more, PA).20
FIG. 1. Characterization of engineered bone-like constructs in vitro.
(a) Photograph of engineered bone 7 days post three-dimensional construct
formation, scale bar¼ 5 mm. (b) Hematoxylin and eosin staining, (c) alkaline
phosphatase (red), (d) alizarin red for calcification, (e) collagen I (green),
(f) collagen II (red), (g) osteocalcin (green), and (h) 4’,6-diamidino-2-
phenylindole staining for nuclei. Scale bar (b through h)¼ 250mm. Color
images available online at www.liebertonline.com/ten.
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Results
BMSCs were cultured on construct dishes in a medium
that induced osteogenic differentiation (M1). Approximately
2 to 4 days after plating, the cells reached confluence and
were switched to a second medium (M2) containing a lower
serum concentration and TGF-b, and two minutien pins were
attached to the culture dish as constraint points. After a
sufficient amount of ECM was produced, the tissue mono-
layer lifted from the substrate and contracted radially. The
placement of the two constraint points inhibited full con-
traction, and the monolayer formed into a cylindroid tissue
construct of approximately 1.5 cm in length and an elliptical
cross-section with major and minor axes of 1.0 .07 mm and
0.78 0.13 mm, respectively (Fig. 1a). EBC formation was
complete within 14 days of plating the BMSCs onto the cell
culture dishes. The resulting engineered tissue was com-
pletely solid, which suggests that the cells within the EBCs
remodeled the tissue during and after construct formation.
The EBCs were kept in culture 7 days or 6 weeks after for-
mation of 3D structure before being fixed for histological and
structural characterization.
At 7 days post-3D EBC formation, constructs were sec-
tioned longitudinally for histological investigation. Hema-
toxylin and eosin (H&E) staining revealed that the
self-assembled EBCs were composed of dense and fibrous
regions (Fig. 1b). The bulk of the tissue stained positive for
ALP activity (Fig. 1c), and calcium deposits were located
throughout the samples, as seen using Alizarin Red staining
(Fig. 1d). The EBCs stained intensely throughout for type I
collagen (Fig. 1e) and lacked type II collagen (Fig. 1f), which
is consistent with the constitution of native bone. At this
point, osteocalcin could not be detected within the EBCs (Fig.
1g). The DAPI-stained cells were fairly uniformly dense
throughout the section (Fig. 1h). TEM verified that the EBCs
contained osteoblasts (Fig. 2a) in a collagenous matrix un-
dergoing mineralization. The diameter of the collagen was
29 4 nm, which corresponds to the diameter of type I col-
lagen found in the femur.21 Mineralization was noted to
occur through matrix vesicles and intrafibrillar calcification
(Fig. 2b, c). Elongated fibroblast-like cells were found on the
periphery of the EBCs within axially aligned unmineralized
type I collagen (Fig. 2d, e). This structure could be inter-
preted as the onset of periosteum development. Wide-angle
X-ray scattering diffraction peak locations for the EBCs cor-
responded with those of hydroxyapatite standard (ICDD:
01-073-0293), verifying that the crystals seen in the TEM
micrographs were indeed hydroxyapatite (Fig. 3).20
The EBCs were able to maintain their size and shape after
pins were removed from the edges. When the constructs
were lifted and held horizontally at one end with forceps,
they did not visibly deflect under their own weight or de-
form under the pinching loads of the forceps. Unlike (un-
mineralized) soft tissue constructs that we have engineered
in our laboratory that contract longitudinally upon con-
straint pin removal and cannot support an axial compressive
load,17 the EBCs resist compressive and bending deforma-
tion. Tension tests performed on EBCs in culture at 7 days
and 6 weeks post-3D EBC formation revealed maximum
tangent moduli of 7.5 0.5 MPa (n¼ 4) and 29 9 MPa
(n¼ 3), respectively. The cross-sectional area remained the
same between 7 days and 6 weeks post-3D construct for-
mation. The tangent moduli are normalized with respect to
the cross-sectional area of the EBCs; therefore, the increase in
stiffness between the two time points is a measure of EBC
phenotype development and not of physical growth.
At 7 days post-3D construct formation, the EBCs were
implanted for 4 weeks between the biceps femoris and
quadriceps of Fisher 344 rats. While implanted, the EBCs
grew and remodeled so that the resulting explant was cy-
lindrical, with a circular cross-section. The diameter of the
explant was 1.6 0.3 mm, equaling the inner diameter of the
FIG. 2. Transmission electron microscopy of engineered
bone-like constructs (EBCs) in vitro. (a) Osteoblast in EBC has
cytoplasmic projections (arrows) and is surrounded by clusters
of mineral (*), scale bar¼ 1.5 mm. (b) Center of tissue shows
mineral clusters (*) where mineralization occurs through ma-
trix vesicles (black arrows); banded collagen I
fibers with an approximate diameter of 30 nm are also seen
(white arrows), scale bar¼ 200 nm. (c) Mineralization also
occurs through intrafibrillar calcification, as indicated by
mineral crystals (arrows) along collagen fibrils, scale
bar¼ 200 nm. (d) Edge of engineered (EB) bone elongated
fibroblast-like cells, which may be the onset of periosteum
development, scale bar¼ 4mm. The boxed area is expanded (e) and shows that the collagen between the fibroblasts in the
fibrous periosteum (FP) lacked mineral crystals, scale bar¼ 300 nm.
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silicone tubing they had been placed in during implantation
(Fig. 4a). H&E staining of the demineralized explants re-
vealed a structure that appeared similar to that of native
bone (Fig. 4b, c).22 Osteocytes in lacunae and blood vessels
were seen throughout the construct (Fig. 4b, c). Further de-
velopment of a periosteum-like structure was seen after im-
plantation, as indicated by the fibrous tissue along the edge
of the bone explants and the neighboring osteoblast-like cells
(Fig. 4b). Alizarin Red staining of explant sections showed
greater amounts of calcification (Fig. 4d) than the construct
engineered in vitro (Fig. 1D). The explanted constructs con-
tained type I collagen and lacked type II (Fig. 4e, f). After
implantation, osteocalcin was present within the bone ex-
plants (Fig. 4g). DAPI staining (Fig. 4h) showed higher cell
densities at regions of lower calcification (Fig. 4d, g vs h).
This phenomenon is similar to that in native tissues, in which
the cell density is lower in mineralized bone than in sur-
rounding fibrous tissues. TEM of the demineralized explants
showed a periosteum-like structure containing osteopro-
genitor cells and rows of osteoblast-like cells (Fig 5a). This
structure is similar to that of native bone, in which osteo-
blasts differentiate from progenitor cells within the perios-
teum in rows and migrate toward the bone matrix.23
Osteocytes in lacunae were seen within the bone matrix
(Fig 5b). Osteoclasts were found throughout the mineral-
ized tissue region (Fig 5c, d). The osteoclasts were identified
via their multinucleation (Fig 5c), ruffled borders, and a
plethora of vacuoles used by the cell for storage of resorbed
material (Fig. 5d).
Discussion
We have developed a method to engineer 3D bone-like
constructs from only BMSCs and their autogenous ECM.
After 7 days of post-3D construct formation, the EBCs ex-
hibited ALP activity and contained mineralized type I col-
lagen. The mechanical properties of the EBCs improved over
time in vitro; tangent stiffness increased by a factor of four
over a 5-week period. No significant physical size change
occurred in vitro from 7 days to 6 weeks in culture after 3D
construct formation, indicating phenotype development due
to tissue remodeling or increased collagen or mineral pro-
duction. The phenotype of the EBCs continued to advance
during implantation in vivo. The explants contained a vascu-
larized bone-like structure with osteoblasts, osteocytes, and
osteoclasts. The cell density was in mineralized regions than
in the surrounding fibrous areas. The explants contained
osteocalcin, which was not detected before implantation, and
qualitatively stained more intensely for mineralization. The
explants also had a functional periosteum-like tissue con-
taining osteoprogenitor cells that were undergoing differen-
tiation to osteoblasts.
The requirements for bone formation in vitro from BMSCs
are ascorbic acid, dex, and an organic phosphate.24 These
three components were administered to the BMSCs during
the cell prolifieration stage of the EBC culture (Table 1).
Ascorbic acid maintains connective tissue and regulates
ATPase, ALP, and protein synthesis in cultures of osteo-
blasts. Dex, a synthetic glucocorticoid, stimulates osteoblastic
and adipogenic differentiation from BMSCs. Phosphates
provide phosphate ions for matrix mineralization.25,26 In a
study published by Maniatopoulos et al., BMSCs were plated
on tissue culture plastic to monitor bone formation from
BMSCs in two dimensions. The BMSCs were cultured in an
osteogenic medium containing ascorbic acid, dex, and an
organic phosphate to form bone nodules.27 Similar to our
EBCs, these nodules exhibited ALP activity, were composed
of mineralized type I collagen and osteocalcin, and contained
osteoblasts and osteocytes. In this previous study, control
dishes that lacked dex contained 5 times more cells than
dishes that received dex. It is hypothesized that the addition
of bFGF to the culture medium allowed for monolayer for-
FIG. 3. Relative intensity
(arbitrary units) vs 2y (de-
grees) plot resulting from
wide angle X-ray scattering of
engineered bone-like con-
structs. Vertical lines denote
the expected peak locations
and the relative intensities of
the hydroxyapatite stan-
dard.20
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mation rather than the formation of bone nodules. bFGF is
commonly used as a potent mitogen for many types of
mesenchymal cells. In bone cultures, this cytokine increases
mineralization, ALP activity, and the concentrations of bone-
specific markers such as calcium and osteocalcin when
administered to BMSCs in an osteogenic medum.27,28 The
mitogenic effects of bFGF in addition to dex in the present
study may have increased proliferation, thus allowing for
monolayer formation rather than the formation of nodules.
Control dishes that received M2 lacking TGF-b formed cell
monolayers that lifted from the substrates but did not
contract into cylindrical constructs (data not shown); thus,
TGF-b is the factor that controls 2D versus 3D construct
formation. Although the overall effects of this growth factor
on BMSCs are not fully known, it is generally used in cul-
ture to stimulate collagen production and matrix maturation
and to induce chondrogenic differentiation from BMSCs.25
In bone cultures, TGF-b regulates osteoblast replication and
migration, increases ALP activity, and stimulates collagen
production and matrix maturation in bone cultures derived
from osteogenic cells and BMSCs.29 We are performing stud-
ies to elucidate the effects of TGF-b on 3D bone construct
formation with the hypothesis that TGF-b increases the rate
of collagen production at an early stage of EBC development
and before full osteogenic differentiation.
After 4 weeks in vivo, the EBCs grew to equal the size of
the tubing they was placed into before implantation. It is
unknown whether the osteoblasts and osteocytes seen in
the EBC explants were derived from the cells present in the
EBCs in vitro or from precursors from the native blood
supply. If some of the osteoblasts and osteocytes developed
from the native tissue, this is an indication that the con-
struct provides an optimal scaffold for bone cell infiltration
and differentiation even though it was placed in an ectopic
site. Explants contained a significant amount of osteocalcin,
but this protein was not found in the EBCs before implan-
tation. Osteoclasts were also found within the mineralized
matrix of the EBC explants. The observation of osteopro-
genitor cells actively differentiating into osteoblasts and the
presence of osteoclasts demonstrates that the EBCs actively
grew and remodeled in vivo in a manner similar to that of
native bone.
FIG. 4. Characterization of engineered bone-like construct (EBC) explants.
(a) Photograph of explant after 4 weeks of implantation, scale bar¼ 5 mm.
(b) Hematoxylin and eosin (H&E) staining of edge of demineralized explant,
fibrous periosteum (FP) on edge of sample, osteoblasts (arrow) differentiat-
ing from osteoprogenitor cells of FP and invading engineered bone (EB).
(c) H&E of center of demineralized engineered bone shows osteocytes (black
arrows) and blood vessels (white arrows). Scale bar of (b) and (c)¼ 62.5 mm.
(d) Alizarin red staining for calcification, (e) collagen I, (f) collagen II,
(g) osteocalcin, (h) and 4’,6-diamidino-2-phenylindole staining for nuclei. Scale bar (d) through (h)¼ 250mm. Color images
available online at www.liebertonline.com/ten.
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Before implantation, the periphery of the EBCd contained
fibroblast-like cells and unmineralized collagen. This phe-
nomenon is unique to this study and has not yet been re-
ported in 2D bone nodules or in bones engineered with
exogenous scaffolding. This structure could be interpreted as
the onset of periosteum development. After implantation for
4 weeks, the engineered tissue developed a functional peri-
osteum, as indicated by the presence of osteoprogenitor cells,
and rows of osteoblasts (Fig. 5A). If the structure on the
periphery of the EBC before implantation was the onset of
the periosteum that continued to develop when implanted
in vivo, it would indicate fibrogenic and osteogenic differ-
entiation from a single cell source in vitro within the same
culture environment. This could suggest that the BMSCs
were differentiating because of the cues delivered through
the medium and preferentially as a result of their location
within the construct or that the cells differentiated into a
mixed population and the fibroblast cells migrated to the
outer periphery of the construct upon formation.
The tangent moduli of the EBC at 7 days and 6 weeks in
culture post-3D construct formation were 7.5 0.5 MPa and
29 9 MPa, respectively. Previous studies have reported the
moduli of unmineralized and mineralized embryonic bone to
be 1.11 MPa and 117 MPa, respectively.30 The mechanical
properties of the EBCs are consistent with developing native
bone because the moduli lie within the limits of native em-
bryonic bone. The tangent modulus is a measure of constitu-
tive stiffness and is independent of construct size; the increase
in EBC tangent moduli between 7 days and 6 weeks in culture
post-3D construct formation is therefore an indication of
phenotype advancement rather than physical growth.
The method of engineering bone-like structures presented
in this study, in which cells are cultured to secrete, assemble,
and mineralize their own 3D scaffolding, bypasses the com-
plexity of engineering a scaffold and shifts the paradigm of
bone tissue engineering to the guided self-assembly of an
autogenous extracellular matrix. Furthermore, this method
uses the culture of BMSCs that can be easily isolated from
autologous sources without major ethical issues and may
be used clinically with minimal risk of rejection. This study
is the first to report a functional periosteum-like structure
around an engineered bone-like tissue, thus further advanc-
ing the state of bone engineering. This novel method of
engineering bone-like tissues can be used as a heuristic ap-
proach to tissue engineer for large bone defect repair or re-
placement without the use of an exogenous scaffold and as a
model for bone formation through intramembranous ossifi-
cation. We believe that these scaffold-less bone constructs not
only contribute significantly to the field of bone engineering,
but also to the field of stem cell research. In this study, os-
teogenic and fibroblastic differentiation of BMSCs resulted
within the same culture environment, suggesting that stem
cells may differentiate because of mechanical signals and
cues from their location relative to other cells in an en-
gineered construct in addition to chemical signals. Me-
chanically constraining the contractile monolayer induces
tensile strain along the major axis of the constructs and
preferentially orients the collagen fibers in this direction.
These are the first 3D, scaffold-less tissues developed from
bone marrow stem cells that demonstrate phenotype ad-
vancement in vitro and in vivo.
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